«Explaining failure of retinoic acid
trials against breast cancer: Timing key.»
Not exact matches
Now a University of Colorado
Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resis
Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids
against some
breast cancers: Because early clinical
trials are often offered to patients who have already tried other more established therapies,
breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resis
cancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.
Previous work has shown that retinoic acid, a chemical that results from the body's natural breakdown of vitamin A, should act
against these CK5 + cells, but clinical
trials of retinoids
against breast cancer have been largely unsuccessful.
Previous
trials of retinoids
against breast cancer have been conducted only after anti-estrogen treatments, at which point, «we were already getting expansion of
cancer stem cells — treating with a retinoid after that was already too late,» Fettig says.
«Agents that block the proteins — CDK4 / 6 inhibitors — have received Food and Drug administration approval for some patients with metastatic
breast cancer, but they've also shown promise
against others types of tumors in clinical
trials.